TBIO — Telesis Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $1.60m
- $3.50m
- $27.51m
Annual cashflow statement for Telesis Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.3 | -18 | -39 | -48.5 | -47.7 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.83 | 1.78 | 4.39 | 5.96 | 18.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.225 | -0.02 | -3.04 | 2.13 | -7.77 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -6.39 | -15.4 | -36.7 | -38.7 | -34.7 |
| Capital Expenditures | -0.079 | -0.204 | -1.85 | -4.47 | -1.98 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -13.2 | -13.5 | -3.76 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.079 | -0.204 | -15 | -18 | -5.74 |
| Financing Cash Flow Items | -0.569 | 0 | -1.37 | -0.752 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 35.1 | -0.096 | 121 | 4.51 | 11.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 28.6 | -15.7 | 69.3 | -52.2 | -28.8 |